Regulators delaying decision on vaccine for 12-17 year olds while studying rare risk of heart inflammation.
U.S. regulators are delaying their decision on Moderna's Covid-19 vaccine for 12- to 17-year-olds while they study the rare risk of heart inflammation, the company said Sunday.
The company also said it will delay filing a request for emergency-use authorization of a lower dose of the vaccine for 6- to 11-year-olds.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna says FDA needs more time to review its Covid vaccine for teensModerna said the FDA needs more time to complete its review of its Covid-19 vaccine for 12-to-17-year-olds before granting emergency use authorization.
Read more »
Moderna says FDA needs more time to complete review of its COVID-19 shot for adolescentsModerna Inc said on Sunday it has been told that the U.S. Food and Drug Administration will require additional time to complete its assessment of the company's COVID-19 vaccine for use in adolescents aged 12 to 17 years.
Read more »
FDA Authorizes Pfizer COVID Vaccine for KidsCoronavirus vaccines should be available for 28 million children in the United States as early as next week
Read more »
FDA Authorizes Use Of Pfizer's COVID-19 Vaccine For Kids 5-11The Food and Drug Administration (FDA) has just authorized Pfizer's COVID-19 vaccine for children ages 5-11.
Read more »
The FDA told Moderna it needs more time to review use of their COVID-19 vaccine for kids'The Company is fully committed to working closely with the FDA to support their review and is grateful to the FDA for their diligence,' Moderna said.
Read more »
Moderna says FDA needs more time to complete review of its COVID-19 shot for adolescentsModerna Inc said on Sunday it has been told that the U.S. Food and Drug Administration will require additional time to complete its assessment of the company's COVID-19 vaccine for use in adolescents aged 12 to 17 years.
Read more »